Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. The Lancet. Haematology Thanarajasingam, G., Minasian, L. M., Bhatnagar, V., Cavalli, F., De Claro, R. A., Dueck, A. C., El-Galaly, T. C., Everest, N., Geissler, J., Gisselbrecht, C., Gormley, N., Gribben, J., Horowitz, M., Ivy, S. P., Jacobson, C. A., Keating, A., Kluetz, P. G., Kwong, Y. L., Little, R. F., Matasar, M. J., Mateos, M. V., McCullough, K., Miller, R. S., Mohty, M., Moreau, P., Morton, L. M., Nagai, S., Nair, A., Nastoupil, L., Robertson, K., Sidana, S., Smedby, K. E., Sonneveld, P., Tzogani, K., van Leeuwen, F. E., Velikova, G., Villa, D., Wingard, J. R., Seymour, J. F., Habermann, T. M. 2022; 9 (5): e374-e384

Abstract

Remarkable improvements in outcomes for many haematological malignancies have been driven primarily by a proliferation of novel therapeutics over the past two decades. Targeted agents, immune and cellular therapies, and combination regimens have adverse event profiles distinct from conventional finite cytotoxic chemotherapies. In 2018, a Commission comprising patient advocates, clinicians, clinical investigators, regulators, biostatisticians, and pharmacists representing a broad range of academic and clinical cancer expertise examined issues of adverse event evaluation in the context of both newer and existing therapies for haematological cancers. The Commission proposed immediate actions and long-term solutions in the current processes in adverse event assessment, patient-reported outcomes in haematological malignancies, toxicities in cellular therapies, long-term toxicity and survivorship in haematological malignancies, issues in regulatory approval from an international perspective, and toxicity reporting in haematological malignancies and the real-world setting. In this follow-up report, the Commission describes progress that has been made in these areas since the initial report.

View details for DOI 10.1016/S2352-3026(22)00045-X

View details for PubMedID 35483398